RxDoctor Payments Data

Margaret Still, MD

Internal Medicine · Roswell, GANPI 1326150251

Payments from drug & device makers

$15,434in general payments, 2019–2025

Across 848 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Pfizer$924
  • Amgen$911
  • AstraZeneca$850
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,2008%
  • Travel & lodging$200%
  • Food & beverage$14,15592%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)155$2,437
Novo Nordisk165$2,251
Biohaven Pharmaceuticals, Inc.5$1,287
Pfizer51$924
Amgen(2 entities)52$911
AstraZeneca(2 entities)52$850
Lilly USA, LLC35$629
GSK37$616
Amarin Pharma, Inc.30$561
Kowa Pharmaceuticals America, Inc.26$366
Otsuka America Pharmaceutical, Inc.13$301
Axsome Therapeutics, Inc.15$295
Astellas Pharma US Inc12$272
Merck18$252
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$239
Eisai Inc.14$230
Boehringer Ingelheim11$211
Takeda Pharmaceuticals U.S.A., Inc.12$210
Bausch Health US, LLC10$204
Esperion Therapeutics, Inc.11$196
Exact Sciences8$171
Amneal Pharmaceuticals LLC9$154
Abbott7$153
Bayer6$117
Biohaven Pharmaceutical Holding Company Ltd.5$115
Inspire Medical Systems, Inc.2$110
Sanofi Pasteur Inc.6$91
Sanofi-aventis U.S. LLC4$83
Idorsia Pharmaceuticals US Inc4$71
Novartis4$65
Mannkind Corporation1$59
Lundbeck LLC3$59
Smith+Nephew1$57
Nalpropion Pharmaceuticals LLC3$56
Ironwood Pharmaceuticals, Inc3$55
Dexcom, Inc.3$55
Currax Pharmaceuticals LLC4$53
Genentech USA, Inc.2$43
Echosens North America, Inc.2$43
Gilead3$42
Paratek Pharmaceuticals, Inc.2$37
Medtronic1$34
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$31
Vivus LLC2$30
Endo Pharmaceuticals Inc.2$30
Shield Therapeutics Inc2$29
Kaleo, Inc.2$29
Therapeuticsmd, Inc.2$28
Aytu Biopharma, Inc.2$27
Nevro Corp.1$25
Vital Connect, Inc1$25
Antares Pharma, Inc.1$20
Philips North America LLC1$19
Sumitomo Pharma America, Inc.1$18
Seqirus USA Inc1$18
Neos Therapeutics, LP1$18
Boston Scientific1$17
Johnson & Johnson1$17
Impel Pharmaceuticals Inc.1$16
IBSA Pharma Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,434 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$345,994
Medicare patients
582
Services billed
9,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$86,644
FarxigaDapagliflozin Propanediol87$84,733
RybelsusSemaglutide42$60,487
EliquisApixaban40$52,126
MounjaroTirzepatide35$38,893
TrulicityDulaglutide23$30,779
VascepaIcosapent Ethyl31$27,215
ArexvyRsvpref3 Antigen/As01e/Pf58$17,590
Breo ElliptaFluticasone/Vilanterol19$15,225
MyrbetriqMirabegron12$13,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,972
SynthroidLevothyroxine Sodium138$11,607
ShingrixVaricella-Zoster Ge/As01b/Pf46$10,087
Estradiol37$5,576
Rosuvastatin Calcium643$4,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,251$147,131115 claims
AstraZenecaFarxiga$850$84,73387 claims
Lilly USA, LLCMounjaro, Trulicity$629$69,67358 claims
GSKArexvy, Breo Ellipta, Trelegy Ellipta, Shingrix$616$55,875135 claims
PfizerEliquis$924$52,12640 claims
Astellas Pharma US IncMyrbetriq$272$13,90212 claims
AbbVieSynthroid$2,437$11,607138 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$154$3,299375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →